Vanguard Capital Management
ALLR

Vanguard Capital Management’s Allarity Therapeutics ALLR Stock Holding History

Vanguard Capital Management’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Hold
171,795
– – ﹤0.01% 3811
2026
Q1 		$187K Buy
+171,795
New +$185K ﹤0.01% 3808

Other funds holding ALLR

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management's ALLR Position: Q2 2026 in Review

Vanguard Capital Management held its Allarity Therapeutics (ALLR) position steady in Q2 2026 at 171,795 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3811.

Vanguard Capital Management first reported a position in ALLR in Q1 2026 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold ALLR as of Q2 2026.

  • Vanguard Capital Management held 171,795 shares of Allarity Therapeutics worth $222K as of Q2 2026.
  • Vanguard Capital Management left its Allarity Therapeutics share count unchanged in Q2 2026.
  • Allarity Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3811 holding.
  • Vanguard Capital Management first reported a position in Allarity Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.